Palliative Systemtherapie des metastasierten Urothelkarzinoms der Harnblase

Das Urothelkarzinom zählt weltweit zu den häufigsten Krebserkrankungen. Im metastasierten Stadium ist die Prognose oft ungünstig. Die Behandlungsmöglichkeiten haben sich in den letzten Jahrzehnten hauptsächlich auf platinbasierte Kombinationstherapien konzentriert. Dieser Review gibt einen Überblick über die Bedeutung der palliativen Systemtherapie in der Behandlung des rezidivierten oder primär metastasierten Harnblasenkarzinoms und konzentriert sich ausschließlich auf die Urothelkarzinome des unteren Harntrakts.

Schlüsselwörter

Harnblasenkarzinom - Urothelkarzinom - metastasiert - Pembrolizumab - Enfortumab vedotin - Erdafitinib

• Literatur

• 1 van Hoogstraten LMC, Vrieling A, van der Heijden AG. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 2023; 20 (05) 287-304
• 2 Burger M, Catto JWF, Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63 (02) 234-241
• 3 von der Maase H, Sengelov L, Roberts JT. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23 (21) 4602-4608
• 4 Bamias A, Aravantinos G, Deliveliotis C. et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22 (02) 220-228
• 5 BellmuntJvon der Maase H, Mead GM. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30 (10) 1107-1113
• 6 Galsky MD, Chen GJ, Oh WK. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012; 23 (02) 406-410
• 7 Galsky MD, Hahn NM, Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29 (17) 2432-2438
• 8 De Santis M, Bellmunt J, Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30 (02) 191-199
• 9 Balar AV, Galsky MD, Rosenberg JE. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76
• 10 Bamias A, Davis ID, Galsky M. et al. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study. Journal of Clinical Oncology 2023; 41 (Suppl. 06) LBA441-LBA441
• 11 Vuky J, Balar AV, Castellano D. et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 2020; 38 (23) 2658-2666
• 12 Powles T, Csőszi T, Özgüroğlu M. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (07) 931-945
• 13 van der Heijden MS, Sonpavde G, Powles T. et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 2023; 389 (19) 1778-1789
• 14 Powles T, Park SH, Caserta C. et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up. J Clin Oncol 2023; 41 (19) 3486-3492
• 15 Aggen DH, Drake CG. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer 2017; 5 (01) 94
• 16 Powles TB, Perez Valderrama B, Gupte S. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology 2023;
• 17 van der Heijden MS, Loriot Y, Durán I. et al. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. Eur Urol 2021; 80 (01) 7-11
• 18 Balar AV, Castellano DE, Grivas P. et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2023; 34 (03) 289-299
• 19 Powles T, Rosenberg JE, Sonpavde GP. et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021; 384 (12) 1125-1135
• 20 Balar AV, McGregor BA, Rosenberg JE. et al. EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. Journal of Clinical Oncology 2021; 39 (Suppl. 06) 394-394
• 21 Helsten T, Elkin S, Arthur E. et al. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res 2016; 22 (01) 259-267
• 22 Loriot Y, Matsubara N, Park SH. et al. Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). Journal of Clinical Oncology 2023; 41 (Suppl. 17) LBA4619-LBA4619
• 23 Bellmunt J, Théodore C, Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27 (27) 4454-4461
• 24 Gomez de Liano Lista A, van Dijk N, de Velasco Oria de Rueda G. et al. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. Eur Urol 2020; 77 (02) 269-276
• 25 Maiorano BA, Catalano M, Maiello E. et al. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?. Front Oncol 2023; 13: 1254906
• 26 Hoimes CJ, Flaig TW, Milowsky MI. et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol 2023; 41 (01) 22-31